logo
Protect your pup naturally with FurLife's Flea & Tick Pendant

Protect your pup naturally with FurLife's Flea & Tick Pendant

New York Post2 days ago
If you want your dog to live a long, itch-less, worry-free life without the harsh chemicals found in traditional treatments, meet FurLife™ — the natural flea and tick solution that dog parents everywhere are switching to.
FurLife's 12-Month Flea & Tick Pendant offers an all-natural, pesticide-free way to protect your dog from fleas, ticks, and mosquitoes — with zero monthly applications and no toxic residues on your dog's coat. It's simple to use, safe for dogs of all sizes, and effective for a full year. FurLife is redefining how modern dog owners approach parasite protection.
Image provided by FurLife
One Pendant. 12 Months. Zero Chemicals.
Most pet owners are familiar with the greasy spot-on treatments or monthly chewables filled with active pesticides. But what if there was a way to protect your dog without toxins or messy applications?
That's exactly what the FurLife Pendant does. It's infused with plant-based essential oils, including cedarwood and spearmint, which naturally repel pests without harming your dog's skin or disrupting their natural microbiome. Simply attach it to your dog's collar — and they're protected for up to 12 months. No monthly reminders. No licking chemicals. No risk to children, puppies, or sensitive pets.
Why Thousands of Pet Parents Are Making the Switch
More and more dog owners are becoming aware of the long-term risks of chemical-based flea and tick treatments — from skin irritation and lethargy, to neurological issues in some cases. FurLife offers an alternative that's backed by nature and supported by happy customers, with over 400,000 dogs already protected across the US and counting.
Here's what makes FurLife stand out:
12 months of protection with just one pendant
No artificial pesticides, permethrin, or DEET
Vet-approved and safe for puppies (12 weeks+) and seniors
Subtle, clean scent that's pleasant for both pets and owners
Eco-friendly and travel-safe — no chemical restrictions when flying
Image provided by FurLife
Prevention Is the Best Protection
FurLife isn't just about avoiding pest infestations — it's about choosing a preventative lifestyle that keeps your dog healthy and comfortable year-round.
Flea and tick bites don't just cause itching — they can transmit serious diseases like Lyme disease, ehrlichiosis, and tapeworms. Protecting your dog before exposure is critical, especially during peak seasons or in high-risk areas.
And unlike chemical treatments that can weaken your dog's liver or irritate their skin, FurLife uses natural repellent ingredients that work with your dog's body — not against it.
The Bottom Line
From city parks to mountain trails, your dog deserves to roam freely — without being a buffet for fleas and ticks. With FurLife, you can offer that freedom without compromising on health or safety. No more greasy chemical applications. No more vet bills from reactions. Just nature's best defense, working quietly on your dog's collar all year long.
Image provided by FurLife
Try FurLife 100% Risk-Free
FurLife believes in their pendant so much, they offer a 30-day money-back guarantee — no questions asked. And because the pendant lasts up to 12 months, that's less than $4 a month for all-natural, all-season protection.
If you don't see a clear reduction in flea and tick activity, you'll get your money back. You can learn more and browse reviews at getfurlife.com — where the FurLife Pendant is available.
This is the future of flea and tick prevention — and it's finally here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

C2N Announces Major Global Expansion, Adds Six New International Partners
C2N Announces Major Global Expansion, Adds Six New International Partners

Business Wire

time17 hours ago

  • Business Wire

C2N Announces Major Global Expansion, Adds Six New International Partners

ST. LOUIS--(BUSINESS WIRE)-- C2N Diagnostics, LLC ('C2N'), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is reaching additional global healthcare providers eager to use its PrecivityAD2™ blood test to help diagnose Alzheimer's disease. The PrecivityAD2™ blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer's disease, for patients being evaluated for cognitive complaints through a simple, non-invasive blood test. Dr. Joel Braunstein, CEO of C2N Diagnostics, says, 'These new international partnerships are intended to broaden access to C2N's innovative Precivity™ portfolio of blood tests in markets facing growing healthcare pressures given aging populations." Share The company has secured partnerships with six new clinical reference laboratories and distributors, expanding its footprint to over seven additional countries. C2N's new partnerships are with: C2N also maintains partnerships with leading labs around the world, including Grupo Fleury, Healius, Mayo Clinic Laboratories, and Unilabs, along with a research collaboration with Mediford. Dr. Joel Braunstein, CEO of C2N Diagnostics, says, 'These new international partnerships are intended to broaden access to C2N's innovative Precivity™ portfolio of blood tests in markets facing growing healthcare pressures given aging populations, a lack of dementia specialists, and inadequate PET infrastructure. These partnerships are a testament to the science and research that have already assisted healthcare providers in delivering a clear picture of Alzheimer's disease pathology to patients and their families in many countries. The growing burden of Alzheimer's disease requires the healthcare system to explore new ways to offer less costly and more accessible diagnostic testing, and we look forward to helping more patients around the world receive an early and accurate diagnosis.' The PrecivityAD2™ blood test involves a simple blood draw from the patient and is intended for patients aged 55 and older with signs or symptoms of cognitive impairment who are undergoing evaluation for Alzheimer's disease or other causes of cognitive decline. PrecivityAD2™ Blood Test is Rigorously Analytically and Clinically Validated; Has High Accuracy The Journal of the American Medical Association (JAMA) published a large clinical care study examining the ability of the PrecivityAD2 blood test algorithm to improve the diagnostic accuracy of Alzheimer's disease in primary care settings, where most patients with cognitive concerns turn to for initial answers about their memory loss. The study found the PrecivityAD2™ test result delivered a highly statistically significant accuracy of over 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis. All C2N's Precivity™ tests are currently performed under the ISO 13485:2016 standard and in the company's CAP accredited, CLIA certified laboratory. About C2N Diagnostics, LLC C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N's high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 150 Alzheimer's disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer's disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer's Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories, and Unilabs. Over 50,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review. The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer's Association. For more information visit

BioMendics Launches TAMES-02 Clinical Trial for Innovative Epidermolysis Bullosa Simplex Therapy
BioMendics Launches TAMES-02 Clinical Trial for Innovative Epidermolysis Bullosa Simplex Therapy

Business Wire

time21 hours ago

  • Business Wire

BioMendics Launches TAMES-02 Clinical Trial for Innovative Epidermolysis Bullosa Simplex Therapy

ROOTSTOWN, Ohio--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of TolaSure™, a first-in-class topical therapy for patients with generalized intermediate to severe Epidermolysis Bullosa Simplex (EB Simplex). "Our early studies with TolaSure showed meaningful reduction in blistering, which is incredibly encouraging for the EB Simplex community." EB Simplex is a rare, inherited skin disorder that causes painful blistering due to fragile skin, affecting an estimated 30,000 to 50,000 individuals worldwide. With current treatment limited to wound care and infection control, patients and families face a lifelong battle without disease-modifying options. TolaSure, developed by BioMendics, aims to change that reality by targeting the mutant keratins that underlie skin fragility, offering a novel mechanism to reduce blister burden and improve quality of life. The TAMES-02 trial builds on the success of the earlier TAMES-01 study, which demonstrated TolaSure's safety and efficacy in adult patients. Dr. Joyce Teng, Principal Investigator at Stanford University, shared: 'Our early studies with TolaSure showed meaningful reduction in blistering, which is incredibly encouraging for the EB Simplex community. Clinical research in rare skin diseases requires collaboration with companies like BioMendics and patient advocacy groups like debra of America to accelerate progress toward transformative therapies. Our shared goal is to bring hope and healing to families who have had so few options for so long.' TAMES-02 is being conducted in partnership with Stanford University School of Medicine and Northwestern University Feinberg School of Medicine—two globally recognized leaders in dermatology research. The trial will evaluate TolaSure in patients aged 4 and older and includes a 2-month double-blind, placebo-controlled phase, followed by a 2-month open-label phase where all participants receive TolaSure, and a 6-month follow-up. Importantly, the trial allows patients to treat plantar (foot) blistering—a major source of pain and disability for those living with EB Simplex. Dr. Amy Paller, Principal Investigator at Northwestern University, added: 'TAMES-02 is a vital next step. The collaboration with BioMendics and Stanford enables us to rigorously evaluate this therapy and, hopefully, bring real progress to patients who have had limited options for far too long.' 'We're really excited to be able to cover travel cost to bring patients in from all over the United States and internationally,' said Dr. Aleesha McCormick Senior clinical research scientist at BioMendics. ' EB Simplex patients don't all live close to an Academic Medical Center like Stanford and Northwestern and our goal is to help as many patients be able to participate in the study as possible. Our study design also lets us recruit slightly less severe patients that may not have flared enough to be eligible for other clinical studies. ' 'Our mission is to bring meaningful therapies to patients living with rare diseases like EB Simplex—conditions that have been overlooked for too long,' said Dr. Karen M. McGuire, CEO and Founder of BioMendics. 'With TolaSure, we're targeting the root cause of blistering by reinforcing fragile keratinocytes. The TAMES-02 trial is a critical step toward proving safety and efficacy. If successful, we'll seek strategic partnerships to help accelerate development and deliver this treatment to patients as quickly as possible. We also see strong potential for TolaSure in other rare keratin disorders such as pachyonychia congenita and epidermolytic ichthyosis.' TAMES-02 reflects BioMendics' ongoing commitment to developing innovative, targeted treatments for rare skin disorders and is currently open for patient enrollment. About BioMendics: For more information about BioMendics please visit our website ( BioMendics is proud to be a REDIzone company at Northeast Ohio Medical University (NEOMED). The REDIzone (Research, Entrepreneurship, Discovery, and Innovation Zone) supports local life science and biomedical entrepreneurs by providing access to NEOMED's resources, expertise, and connections to the region's innovation ecosystem. This partnership has been instrumental in advancing TolaSure from research to clinical development.

mPulse Sees Accelerated Revenue Growth and Product Adoption in First Half of 2025
mPulse Sees Accelerated Revenue Growth and Product Adoption in First Half of 2025

Business Wire

time21 hours ago

  • Business Wire

mPulse Sees Accelerated Revenue Growth and Product Adoption in First Half of 2025

LOS ANGELES--(BUSINESS WIRE)-- mPulse, a leading provider of Health Experience and Insights (HXI) technology, today announced accelerated financial performance in the first half of 2025 driven by sales of multi-product solutions across its predictive analytics, omnichannel engagement and health portal products. mPulse's integrated solutions are being adopted by both large national and regional health plans and are driving strategic expansion and net new customer growth. mPulse's multi-product HXI solutions address key efficiency challenges and drive better outcomes across the health consumer journey. The company's unified member 360 data allows health plans to visualize the consumer journey with outcomes and engagement data that are automatically captured to enable closed-loop analytics and continuous optimization. mPulse's partnerships with over 400 healthcare organizations, including 40 of the 50 largest health plans, are driving innovation and enhanced product offerings. "The rapid adoption of mPulse's multi-product solutions by leading health plans is a clear indicator that HXI is addressing core challenges in the market,' said Bob Farrell, CEO of mPulse. 'Engagement programs are driving portal utilization so health plans are realizing much higher value from their technology investments. Our unified member 360 data is providing a single view across departments which dramatically streamlines processes and enables highly tailored member experiences.' On the heels of its Q1 and Q2 2025 market momentum, mPulse was also recently recognized in Gartner® Hype Cycle™ for US Healthcare Payers, 2025 for the 4th year in a row across the Health Navigation Solutions and Digital Broker categories. The report focuses on payor technologies and deployment approaches that enable digital optimization of current business processes and transformational technologies that promise high strategic value. The mPulse team believes this inclusion as a Sample Vendor across categories to be an indicator of the broad value HXI capabilities deliver to support healthcare payors and their digital strategies. Amidst it's strong growth and recent industry recognition, mPulse also announced Activate2025, the industry's premier Health Experience and Insights conference for healthcare executives to learn, network, and celebrate innovative health engagement. This year's event, themed ' Building Trust for Better Outcomes: Digital Strategies to Empower the Consumer Health Experience', will convene healthcare and technology thought leaders in Austin, Texas from September 23-24, 2025. The event will feature renowned keynote speakers, Chiquita Brooks-LaSure and Kate O'Neill, who will bring their decades of experience and expertise to event participants. Sessions will focus on connecting key member experience technologies, with specific tracks on technology solutions to drive performance across focus areas of the One Big Beautiful Bill including Medicaid work requirements and stricter enrollment and retention requirements for FFM plans. To see how mPulse can support your organization, visit our website here or for more information or to register for Activate2025, visit here. About Gartner Gartner, Hype Cycle for U.S. Healthcare Payers, 2025, Robert Potts, Connie Salgy, Austynn Eubank, 16 June 2025 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About mPulse mPulse, a leader in digital solutions for the healthcare industry, is transforming consumer experiences to deliver better, more equitable health outcomes. By combining AI-powered analytics, omnichannel outreach and digital health navigation technology, mPulse creates personalized health journeys and provides advanced insights to power collaboration across the healthcare ecosystem. With over a decade of experience and 4 billion consumer touchpoints annually, mPulse is the trusted Health Experience and Insights (HXI) partner for over 400 healthcare organizations. To learn more, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store